ANDA 91332, held by Lupin. Ethinyl Estradiol; Norethindrone.
As of Nov 16, 2026, ANDA 91332 (Norethindrone And Ethinyl Estradiol And Ferrous Fumarate), held by Lupin, was first approved by FDA on Mar 23, 2016, with 4 approved supplements and 0 published complete response letters.
WYMZYA TM Fe is indicated for use by females of reproductive potential to prevent pregnancy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 23, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone And Ethinyl Estradiol And Ferrous Fumarate0.035MG;0.4MG · tablet;oral | Ethinyl Estradiol; Norethindrone | Rx |
| Apr 29, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 5, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 5, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 5, 2020 | Supplement 7Manufacturing | Approved | None posted |
| Mar 23, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters